RT Journal Article
SR Electronic
T1 Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 329
OP 335
DO 10.3949/ccjm.89a.21003
VO 89
IS 6
A1 Ghaith Alhatemi
A1 Mohamed Zghouzi
A1 Yasar Sattar
A1 Bachar Ahmad
A1 Waqas Ullah
A1 M. Chadi Alraies
YR 2022
UL http://www.ccjm.org/content/89/6/329.abstract
AB New-onset post-cardiac surgery atrial fibrillation (PCSAF) is a frequent complication with estimated incidence of 17% to 64%, depending on type of surgery. It is associated with higher mortality, morbidity, and predisposition to stroke and systemic embolism postoperatively. Standard care involves rate or rhythm control, in addition to antithrombotic therapy in those with history of stroke, transient ischemic attack, or high risk of systemic thromboembolism. However, risk of bleeding is not negligible, and treating physicians should weigh the risks and benefits before committing to postoperative anticoagulation therapy. More investigations are warranted to explore antithrombotic therapy benefit, particularly postoperative anticoagulation, considering the potentially self-limited nature of the arrhythmia and high risk of postoperative bleeding.